Since an elevated antioxidant capacity is a defining trait of breast cancers with poor treatment responses, the authors demonstrate that pharmacological inhibition of ERRα/γ enhances the antitumor efficacy of the chemotherapeutic paclitaxel on tumor organoids [55]. Here, ESRRA is linked to breast cancer.